Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ
Work
Year: 2023
Type: article
Abstract: Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR)α and β/δ agonist that has reached a phase III clinical trial for the treatment of metabolic dysfunction-associated steatotic liv... more
Source: Biomedicine & Pharmacotherapy
Institutions Instituto de Salud Carlos III, Universitat de Barcelona, Hospital Sant Joan de Déu Barcelona, Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Investigaciones Biomédicas Sols-Morreale +11 more
Cites: 52
Cited by: 8
Related to: 10
FWCI: 1.652
Citation percentile (by year/subfield): 68.78
Subfield: Molecular Biology
Domain: Life Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $2,660